The Malaria Initiative
The Novartis Malaria Initiative focuses on improving access to treatment, helping communities in malaria-endemic countries deliver better healthcare and investing in research and development into the next generation of antimalarials. Over the past decade, the initiative has become one of the largest access-to-medicine programs in the healthcare industry, measured by the number of patients reached annually.
Since 2001, working with a range of organizations, we have provided more than 600 million treatments for adults and children, without profit, to more than 60 malaria-endemic countries, contributing to a significant reduction of the death toll from malaria, mostly infants and children. We are proud of the remarkable public health milestones these collaborations have helped to achieve.
- Launch of Dispersible artemether-lumefantrine with MMV
- Artemether-lumefantrine is the first ACT approved by the US FDA
- Prix Galien USA
- World Business and Development Award, United Nations
- Award for Corporate Social Responsibility by the Association of Strategic Alliance Professionals